Via Bioworld
“There has been buzz that the company’s solution could help those affected by COVID-19. During the company’s March 3 fourth-quarter earnings call, Jeffrey Cohen with Ladenburg Thalmann asked whether the company was aware of any COVID-19 patients who had been treated with Aquadex. Cohen noted that he had seen a couple of blog posts and had inbound calls about this topic.”
“’Interesting enough is just this week, we’ve had a couple of inquiries,’ [CHF Solutions CEO John] Erb replied. ‘So, we’re pursuing that at this time. We also are pursuing it internationally because we have some strong use of our product in Italy, where there’s certainly a large number of patients with coronavirus. So, it’s at hand, we’re looking into it, and I think there’ll be an opportunity for us to help,’ he added.”
Read the rest of “CHF Solutions looks to bring its tech to help COVID-19 patients” on Bioworld
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.
